Sonoma to Present Data from Novel Treg Therapy for Rheumatoid Arthritis
Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy at Symposium on Hidradenitis Suppurativa Advances
Sonoma Biotherapeutics Appoints Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced that its Co-founder and Chief Executive Officer, Jeffrey Bluestone, Ph.D., has been elected to the National Academy of Sciences (NAS), in recognition of his groundbreaking achievements in immunology and original research.
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
Regulatory T cell-focused Sonoma Biotherapeutics has been following a slow and steady path ever since bringing in a whopping $265 million in a 2021 fundraising round, one of the largest of the year.
Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2022
SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the appointment of Jessica Stitt as Chief Financial Officer. Stitt has over 20 years of healthcare finance, strategy, and leadership experience and has participated in the execution of nearly $2 billion in corporate financing transactions. She will join Sonoma Biotherapeutics’ executive leadership team and oversee the company’s finance, accounting, information technology, communications, and investor relations functions.
A year after Jeff Bluestone’s Sonoma Biotherapeutics netted $265 million in a huge Series B, the biotech is now looking to establish itself in the manufacturing ecosystem of the Pacific Northwest.
SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Sonoma Biotherapeutics, an immune tolerance company focused on the development of novel regulatory T cell (Treg) therapies for autoimmune and inflammatory disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to initiate a Phase 1 study of SBT115301 in healthy participants. SBT115301 is a biologic designed to eliminate highly activated effector T cells (Teff) that are dominant in autoimmune and inflammatory disease.